I need to read through this 10-Q filing carefully to extract the key financial and operational disclosures before writing the article. The filing is Arvinas, Inc.'s Form 10-Q for the quarterly period ended September 30, 2026, filed November 3, 2026. The ticker is ARVN on The Nasdaq Stock Market LLC (NASDAQ:ARVN). As of October 30, 2026, there were 65,485,006 shares outstanding. However, the filing content provided is largely the cover page, table of contents, and forward-looking statements cautionary note. The actual financial statements, MD&A, and other substantive disclosures are not included in the extracted text. I need to assess whether there is enough substantive content (excluding boilerplate) to exceed 150 words. Substantive content I can identify: - Quarterly period: September 30, 2026 - Shares outstanding: 65,485,006 as of October 30, 2026 - Accelerated filer status - Pipeline mentions: ARV-393, ARV-027, ARV-6723, ARV-102, ARV-806 - Cash sufficiency statement: "into the second half of 2028" - License agreements with Pfizer Inc. and Rigel Pharmaceuticals, Inc., and Novartis Pharma AG - Yale University amended and restated license agreement - Clinical trial details mentioned in forward-looking statements - Chief medical officer search mentioned The forward-looking statements section does contain substantive pipeline and financial disclosures (even if forward-looking), exceeding 150 words. I'll proceed with the article, being careful to attribute all forward-looking statements as the company's own.

Arvinas, Inc. (NASDAQ:ARVN) filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 3, 2026, disclosing share count, pipeline status, and cash runway guidance among other items.

Key Highlights

  • Shares outstanding: As of October 30, 2026, Arvinas had 65,485,006 shares of common stock, $0.001 par value per share, outstanding.
  • Filer status: The company is classified as an accelerated filer for the period covered by this report.
  • Cash runway guidance: According to the filing, the company believes its cash, cash equivalents, restricted cash, and marketable securities are sufficient to fund planned operating expenses and capital expenditure requirements "into the second half of 2028."
  • Active pipeline programs: The filing identifies ARV-393, ARV-027, ARV-6723, and ARV-102 as current clinical-stage candidates, and ARV-806 as a program for which the company disclosed plans to seek an out-licensing agreement for additional clinical trials.
  • Key collaborations: The company disclosed license agreements with Pfizer Inc. and Rigel Pharmaceuticals, Inc., as well as a license agreement with Novartis Pharma AG, with potential milestone payments and royalties referenced.
  • Leadership: The filing references the company's ability to manage the search for a new chief medical officer as a forward-looking item.

Arvinas Q3 2026: Pipeline Updates, Cash Runway, and Operational Disclosures

Arvinas, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, covering financial results and operational disclosures for the three months through that date. The company, headquartered at 395 Winchester Ave., New Haven, Connecticut, is listed on NASDAQ:ARVN with a Commission File Number of 001-38672. As of October 30, 2026, the registrant reported 65,485,006 shares of common stock outstanding at a par value of $0.001 per share.

The filing's forward-looking statements section, which the company cautions are subject to substantial risks and uncertainties, outlines several program-specific expectations. Regarding ARV-393, the company stated its belief that the candidate "can be an attractive combination partner for development of novel therapies for lymphoma, including chemo-free combination regimens and/or 'all oral' treatment options." For ARV-027, the company stated its belief that the candidate "has the potential to become the first treatment option for patients with spinal bulbar muscular atrophy ('SBMA'), where no therapies have been approved in the U.S. or European Union." The filing also references plans for ARV-102, including initiation of a Phase 1b trial in patients with progressive supranuclear palsy in the European Union and the United Kingdom, pending clinical trial application submission and regulatory authorization. All such statements are the company's own and are subject to its cautionary language regarding forward-looking disclosures.

The company disclosed license agreements with Pfizer Inc. and Rigel Pharmaceuticals, Inc. and a separate license agreement with Novartis Pharma AG, noting potential milestone payments and royalties under those arrangements. An amended and restated license agreement with Yale University is also referenced. For ARV-806, the company disclosed plans to seek an out-licensing agreement for any additional clinical trials, including dose expansion or combination trials. The filing also notes the company's ongoing search for a new chief medical officer.

What Was Disclosed

Arvinas filed its September 30, 2026 quarterly report disclosing 65,485,006 shares outstanding, an accelerated filer designation, cash runway guidance into the second half of 2028, active clinical programs across four candidates, and licensing arrangements with Pfizer, Rigel, and Novartis.